Clinical Trials Logo

FGFR2 Gene Mutation clinical trials

View clinical trials related to FGFR2 Gene Mutation.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05052372 Terminated - Bladder Cancer Clinical Trials

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Start date: November 21, 2021
Phase:
Study type: Observational

Bladder cancers are associated with genetic mutations that are present in the patient's bladder or urothelium, the lining of the lower urinary tract. Fibroblast growth factor (FGFR) alterations are present in approximately one in five patients with recurrent and refractory bladder cancer. This study will collect biomarker data from subjects receiving erdafitinib to further investigate the relationship between treatment with erdafitinib and clinical response, progression, and/or genetic alterations.

NCT ID: NCT03773302 Terminated - Clinical trials for Advanced Cholangiocarcinoma

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Start date: December 27, 2019
Phase: Phase 3
Study type: Interventional

Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma. The purpose of the study is to evaluate the efficacy and safety of the investigational agent oral infigratinib vs standard of care chemotherapy (gemcitabine plus cisplatin) in first-line treatment of participants with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion/rearrangement. Subjects will be randomized 2:1 to receive infigratinib or gemcitabine plus cisplatin.

NCT ID: NCT02706691 Terminated - Clinical trials for Head and Neck Squamous Cell Carcinoma

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Start date: June 1, 2018
Phase: Phase 2
Study type: Interventional

This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has returned after a period of improvement. BGJ398 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02150967 Terminated - Clinical trials for Advanced Cholangiocarcinoma

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Start date: July 23, 2014
Phase: Phase 2
Study type: Interventional

This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic alterations.